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Summary. Patients with connective tissue disease (CTD) 
who are prone to developed isolated pu lmonary  hyper-  
tension (PH) are pr imar i ly  young females with a history 
of  Raynaud 's  phenomenon associated with an exert ional  
dyspnoea.  F rom the start of  the disease, pu lmonary  func- 
t ion tests show a decreased iffusing capacity for carbon 
monoxide,  while X- ray examinat ion shows no obvious 
abnormal i t ies uch as interstit ial  f ibrosis. Al l  pat ients 
show, on e lectrocardiographic  examinat ion,  evidence of  
r ight axis deviat ion and right ventr icular hypertrophy.  It
has been suggested that PH is found most ly  in patients 
with systemic scerlosis character ized by the CREST syn- 
drome. The h istopathologica l  f indings are int imal prol i f-  
erat ion, narrowing of  the vessel umen and medial  f ibro- 
sis. These are not  specific for CTD.  One would expect 
more signs of  vasculitis. Nei ther  signs of  lung fibrosis, 
nor signs of  pu lmonary  embol i  are described. 
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Introduction 
Between 1977 and 1989 a diagnosis of  isolated pul- 
monary  hypertension (PH) was made before death in 
only three patients who visited our outpat ient  clinic for 
connective tissue diseases (CTD).  Becaue PH is a rather 
uncommon compl icat ion o f  CTD,  we reviewed the litera- 
ture on different aspects of  PH such as sex, age of  disease 
onset and clinical and laboratory  characteristics. The 
purpose of  this study was to determine the characterist ics 
of  patients with CTD who develop PH, and to decide 
whether or not they form a separate ntity. 
Case reports (Table 1) 
Patient A was a forty-year-old woman who presented with a 2-year 
history of fatigue, polyarthritis, Raynaud's phenomenon and a but- 
terfly rash on the face. Anti-dsDNA was doubtfully positive and 
anti-ENA was positive. A diagnosis of Systemic Lupus Erythemato- 
sus (SLE) was made and treatment with hydroxychloro-quinesul- 
fate was initiated. 
Six months later the patient presented with pleuropericarditis, 
which was treated with corticosteroids. Two years later she devel- 
oped severe dyspnoea. Examination revealed a heart rate of 72 beats 
per minute, a blood pressure of 120/80 and an elevated jugular 
venous pressure. There was acrocyanosis, a butterfly rash on the 
face, purpura of the face and the extremities and an accentuated 
pulmonary second sound. 
A lung scan showed no evidence of pulmonary emboli. Cardiac 
catheterization revealed a systolic pulmonary artery pressure of 
75 mm Hg, and a diastolic pulmonary artery pressure of 43 mm Hg. 
No cardiac or pulmonary conditions were found that might have 
been responsible for the PH. Shortly after cardiac atheterization 
the patient developed severe cardiac failure from which she died. 
An autopsy revealed right ventricular hypertrophy, dilatation of 
the right atrium and arteritis necroticans of the lungs. There were 
no 'signs of lung fibrosis or pulmonary emboli that could account 
for the existence of PH. 
Patient B was a 56-year-old woman who presented with exertional 
dyspnoea, fatigue and Raynaud's phenomenon. She was examined 
initially by a pulmonologist. Physical examination revealed a heart 
rate of 140 beats per minute, ablood pressure of 130/80 and oedema 
of the ankles. There were no abnormalities of the heart or the lungs. 
Laboratory investigations showed an elevated erythrocyte s dimen- 
tation rate; Latex and Waaler-Rose tests were positive. 
Table 1. See text 
Age Sex Clinical symptoms Serologic 
abnormalities 
Patient A 40 Female Raynaud, polyarthritis, Anti ds DNA 
butterfly rash, pleuro- pos, 
pericarditis, dyspnoea ENA pos 
PatientB 56 Female Raynaud, dyspnoea ANA pos 
Anticentromere 
antibodies pos 
Rose test pos 
Patient C 30 Female Raynaud, arthritis, ANApos 
dyspnoea Anti RNP pos 
Rose test pos 
84 
Pulmonary function tests showed normal spirometry, but the 
diffusing capacity for carbon monoxide was markedly reduced 
(< 50% of predicted). No treatment was initiated. 
A few months later physical examination revealed a dry and 
"tight" skin and facial telangiectasias. Laboratory investigations 
revealed a creatinine clearance of 42 ml/min; anticentromere anti- 
bodies were positive to a titre of t 0 240. An X-ray of the oesophagus 
showed ecreased motility. It was assumed that the patient suffered 
from systemic sclerosis. 
One month later physical examination revealed acrocyanosis, 
the murmur of tricuspid incomptence was heard, and there was 
oedema of the ankles. Electrocardiography s owed right axis devi- 
ation and signs of right ventricular hypertrophy. 
Two months later she was admitted to hospital because of severe 
exertional dyspnoea, orthopnoea, palpitations and dizziness on ef- 
fort. Physical examination revealed a heart rate of 80 beats per 
minute, a blood pressure of 100/60, an elevated jugular venous 
pressure, cyanosis of the lips and the acra, a tricuspid incompetence 
murmur, pitting oedema of the ankles and a "tight" skin. Chest 
X-ray showed cardiomegaly. A lung scan was normal. Echocardiog- 
raphy revealed a pericardial effusion and incompetence of the tri- 
cuspid and pulmonary valves. Cardiac catheterization revealed a 
systolic pulmonary artery pressure of 55 mmHg and a diastolic 
pulmonary artery pressure of 20 mm Hg. Pulmonary wedge pres- 
sure was normal. Pulmonary function tests were unchanged. 
Treatment with diuretics, ACE-inhibitors and isosorbide-dini- 
trate was started. Her complaints of severe exertional dyspnoea, 
orthopnoea, fatigue and dizziness on effort continued. Treatment 
was started therefore with corticosteroids, cyclophosphamide, va-
sodilators, digitalis and diuretics. Nevertheless a rapidly progressive 
cardiac failure developed with severe hypoxemia from which the 
patient died. 
An autopsy revealed right ventricular hypertrophy, dilatation of 
the right atrium and the right ventricle and there were no signs of 
pulmonary emboli, infarctions or fibrosis. The pulmonary arteries 
showed extensive, partly obliterative, intimal fibrosis. 
Patient C is a 30-year-old women who presented with pain in the 
hands, feet and neck, fatigue, a/-year history on Raynaud's phe- 
nomenon, atypical chest pain and exertional dyspnoea. Physical 
examination revealed a heart rate of 76 beats per minute, a blood 
pressure of 110/80 and a normal venous pressure. The heart seemed 
enlarged and a loud pulmonary second sound and a systolic mur- 
mur were heard. The palms of the hands were swollen. 
Laboratory investigations revealed apositive Waaler-Rose test, 
positive ANA, a positive anti-RNP and an elevated CPK. Chest 
X-ray showed cardiomegaly; the lungs were normal. Electrocardio- 
graphy showed right axis deviation and a pattern of right ventricu- 
lar hypertrophy. Echocardiography revealed ilatation of the right 
atrium and the right ventricle and imcompetence of the tricuspid 
valve. Cardiac catheterization revealed a systolic pulmonary artery 
pressure of 68 mm Hg and a diastolic pulmonary artery pressure of 
24 mm Hg. The severe tricuspid incompetence was confirmed. Pul- 
monary function tests showed a normal diffusing capacity for car- 
bon monoxide. Treatment was started with corticosteroids, cy- 
clophosphamide and vasodilators. To date, the clinical condition of 
the patient has been quite good. Some of the clinical and laboratory 
characteristics of the three patients are summarized in Table 1. 
Review of the literature 
PH is a serious complication of  CTD, which has been 
reported with increasing frequency during the last 
decade. PH until now, has been described mostly in pro- 
gressive systemic sclerosis (PSS), particularly in the 
CREST syndrome variety. SLE and the closely related 
mixed connective tissue disease (MCTD)  account for the 
majority of  cases in the other CTD groups. PH is rarely 
Table 2. Isolated pulmonary hypertension i  the CREST syn- 
drome [t] 
CREST-PH CREST-noPH 
(n = 20) (n = 287) 
Incidence _+ 4.5% 
Mean age at disease onset 42 years 41 years 
Sex % female 80% 83% 
Raynaud's phenomenon 100% 68% 
ANA positive 44% 37% 
Anticentromere antibodies 53% 46% 
Rheuma factor positive 13 % 13 % 
DLCO <45% of predicted 65% 13% 
seen in rheumatoid arthritis (RA). In this review a de- 
scription will be given of  the clinical and laboratory char- 
acteristics of  PH in PSS, the CREST syndrome variety of  
PSS, SLE and RA. 
Progressive systemic sclerosis 
A large-scale study of  673 systemic sclerosis patients has 
been performed by Stupi et al. [1]. In 59 patients (9%) PH 
occurred during the disease course. In 30 patients, all 
with the CREST syndrome, the PH was isolated, i.e. in- 
dependent of  other pulmonary or cardiac conditions. Be- 
cause PH is one of  the main causes of  death among pa- 
tients with the CREST variant, the investigators tried to 
identify clinical and laboratory characteristics that might 
severe as predictors of  this complication. Twenty patients 
with isolated PH and 287 patients without PH could be 
described in detail. Some of  the clinical and laboratory 
characteristics are summarized in Table 2. At the time of  
diagnosis of  PH, the most common cardiopulmonary 
symptom in the 20 patients was exertional dyspnoea. In 
17 of  the 20 patients this symptom was present for less 
than 1 year prior to the diagnosis o fPH.  Orthopnoea was 
noted in 35% of the patients. 
Electrocardiographic evidence of  right axis deviation 
was noted in all 20 PH patients, and 19 patients and 
evidence of  right ventricular hypertrophy. In 18 of  the 20 
PH patients, chest X-rays showed right ventricular en- 
largement, as well as prominent enlargement of  the pul- 
monary  arteries. However, no signs of  pulmonary inter- 
stitial fibrosis were observed. The diffusing capacity for 
carbon monoxide was strikingly reduced in the group of  
patients with PH. Six PH patients underwent pulmonary 
function testing 1 to 6 years before confirmation of  PH. 
All six had a severely reduced DLCO.  Of  the 20 patients, 
only one remained alive; death was in general attributed 
to cor pulmonale. The most common vascular changes in 
PH at autopsy were smooth muscle hyperplasia nd inti- 
real fibrosis. 
Salerni et al. [2] have described 10 patients with severe 
PH without pulmonary fibrosis in the CREST syndrome. 
Some of the main clinical and laboratory characteristics 
are summarized in Table 3. The characteristic histologi- 
cal finding they have described was intimal proliferation 
with narrowing of the vessel lumen in the small and 
medium sized pulmonary arteries and arterioles. They 
have also found immunoglobulin IgG and complement 
component Clq in the pulmonary vessels. 
Owens et al. [3, 4] have reported yspnoea on exertion 
and at rest, pleuritic hest pain and a chronic nonproduc- 
tive cough as the main clinical symptoms. Summarizing 
the above reports [1-4] the most important histopatho- 
logical findings in PH patients indicate avascular disease 
rather than a disease of pulmonary (interstitial fibrosis) 
origin [5]. Furthermore the disease seems to be restricted 
to the CREST variant of PSS. 
Systemic lupus erythematosis (SLE). Cases of PH in SLE 
have been documented by different authors. Some of the 
characteristics are summarized in Table 4 [6-10]. In all 
documented case reports the clinical and laboratory char- 
acteristics of PH are similar to those described in systemic 
sclerosis and the CREST variant. Pulmonary function 
tests show a decreased iffusion capacity for carbon 
monoxide in the majority of cases. The occurrence of PH 
appears unrelated to the severity of SLE activity [8]. It 
always appears suddenly in the disease course with a 
steady down-hill progression, despite therapy. Serologi- 
cally some features are noteworthy. The incidence of 
RNP positivity, often in high titres, is greater than the 
25% average occurring in SLE [8]. Quismorio et al. [9] 
has described a high frequency of rheumatoid factors; i.e. 
in 9 of 11 patients. A high incidence of the "lupus antico- 
agulant" has been reported by others [10]. 
Pathological studies of the pulmonary vasculature 
have revealed intimal fibrosis with occasional oblitera- 
tion of the lumen, medial fibrosis and in few occasions 
fibrinoid necrosis and signs of vasculitis [6, 8, 9]. Again 
there are no signs of lung fibrosis or pulmonary emboli 
that could account for the existence of PH. 
Table 3. Pulmonary hypertension in the CREST syndrome (  = 10) 
[21 
Reported incidence (CREST) 
Mean age at disease onset 
Sex % female 
Raynaud's phenomenon 







Multiple etiological factors have been suggested in the 
pathogenesis of PH in SLE. The association between 
Raynaud's phenomenon and PH in SLE has been re- 
ported by different authors [9, 11]. 
In conclusion, it appears that in cases of PH in SLE, 
the clinical signs and the course of the disease are similar 
to systemic sclerosis. 
Rheumatoid arthritis. PH is uncommon in RA and has 
been infrequently reported in the literature. Between 1971 
and 1983, three patients with classical RA who developed 
PH have been described y Asherson et al. [12]. 
All patients were female and developed PH late in the 
course of their rheumatoid disease. Raynaud's phe- 
nomenon was present in only one patient. One patient 
had established pulmonary disease with mild pulmonary 
fibrosis; another may have had thromboembolic disease, 
while in the third patient here were no obvious patho- 
genetic factors for PH. Definitive histological diagnosis 
of the type of PH could not be made because of absence 
of pathological data. 
Discussion 
PH is a serious complication of CTD that is being in- 
creasingly reported in the literature, but fortunately it is 
relatively uncommon. We were able to diagnose PH be- 
fore death in three patients who visited our outpatient 
clinic or rheumatic diseases. This clinic is a referral centre 
for the southwest of The Netherlands which has a popu- 
lation of 2.5 million. Annually, 1500 new patients are 
referred to our outpatient clinic. A rough calculation sug- 
gests that the incidence of PH is 1:6000 new referred 
patients. 
Patient A suffered from SLE and developed PH, inde- 
pendent of pulmonary or cardiac onditions. In patient B 
and C it was not possible to make a firm diagnosis, pa- 
tient B did not meet all the criteria of systemic sclerosis 
nor of the CREST syndrome variant. To date, patient C 
does not fulfill the criteria for SLE or MCTD, nor for 
PSS. Also, in these two patients the PH was isolated. 
Although a common diagnosis could not be made in 
these three patients, they showed similar clinical and lab- 
Table 4. Pulmonary hypertension in SLE. =not reported 
Authors (year) Reference Incidence Age range Sex Raynaud's 
(number of patients) in SLE (%) (X) % female phenomenon (%) 
Perez and Kramer (1981) [6] 9 17-53 years 100 75 
(n =4) (38) 
Hodson et al. (1983) [7] 3 21-31 years 100 100 
(n=4) (27) 
Asheron and Oakley (1986) [8] - 19-47 years 66 50 
(n=6) (30) 
Quismorio et al. (1984) [9] 0.5 21-45 years 95 73 
(n=20) (30.9) 
Asheron et al. (1986) [10] 18 49 years 90 75 
(n = 64) 
86 
oratory characteristics. All patients were female and rela- 
tively young at disease onset. There was a history of 
Raynaud's phenomenon and dyspnoea. Serologically 
ANA were positive in all patients and patient B and C 
had a positive Waaler-Rose test. Furthermore, the three 
patients howed the same clinical and laboratory charac- 
teristics that are associated with PH. 
Evaluation of the literature on different aspects of PH 
in CTD shows that nearly all the patients are females. 
The age of disease onset varies from 18 to 50 years and is 
mostly around 30 years. Raynaud's phenomenon is pres- 
ent in all the patients with systemic sclerosis. In SLE, 
Raynaud's phenomenon is present in 75% of the patients 
with PH. The most important clinical symptom associ- 
ated with PH is dyspnoea on exertion. 
In most patients with PH, electrocardiographic evi- 
dence of right axis deviation and right ventricular hyper- 
trophy is noted. Chest X-rays show right ventricular en- 
largement and prominent pulmonary arteries, while there 
are no signs of pulmonary interstitial fibrosis. Pulmonary 
function tests show only mild abnormalities, with the 
exception of the diffusion capacity for carbon monoxide 
which is strikingly reduced in patients with isolated PH in 
the CREST syndrome as well as in SLE. It has been 
emphasized by Stupi et al. that the diffusing capacity for 
carbon monoxide might be of predictive value in the de- 
velopment of PH [1]. They conclude that patients with a 
decreased iffusing capacity should be considered to be 
at risk for the development of PH. 
There are no serologic abnormalities that predict, or 
correlat with the development of PH. However, some 
serologic features are noteworthy. The incidence of RNP 
positivity in patients with PH is greater than the average 
of 25% occurring in SLE [8]. A high frequency of 
rheumatoid factors has been described by Quismorio 
et al. [9], while a high incidence of the lupus anticoagu- 
lant has been reported by Asherson et al. [10]. 
In the cases we reported, patient B and C had a posi- 
tive Waaler-Rose test. The characteristic histological 
findings in patients with PH are similar to those found in 
systemic sclerosis, the CREST syndrome and in SLE. The 
histopathological changes involving the small and medium 
sized arteries and arterioles consist of intimal fibrosis 
with narrowing of the vessel umen, smooth muscle hy- 
perplasia and medial fibrosis. These histopathological 
findings are also characteristic of isolated or primary PH, 
as has been described by Wagenvoort and Wagenvoort 
[13, 14], and seems to be the consequence of PH itself. In 
none of the cases of PH that were described in this article 
were there signs of interstitial fibrosis or pulmonary em- 
boli that could account for the existence of PH. 
Although multiple etiological factors have been sug- 
gested in the pathogenesis of PH, the etiology remains 
unclear. We can only conclude that patients who develop 
PH in CTD are young females with a history of Ray- 
naud's phenomenon and dyspnoea on exertion. RNP 
positivity as well as positive rheumatoid factors and the 
lupus anticoagulant may be present. Pulmonary function 
tests show a strikingly decreased iffusing capacity for 
carbon monoxide. The histopathological changes consist 
of intimal proliferation, narrowing of the vessel umen 
and medial fibrosis. These characteristics are indepen- 
dent of the type of CTD that has been diagnosed. There- 
fore we conclude that PH forms a distinct syndrome 
within the group of patients with CTD. 
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